Steve Harr

Co-founder and CEO at Sana Biotechnology
Seattle

Steve Harr is the co-founder and CEO at Sana. He founded Sana, which went public and where he continues to lead.

Gillian Dohrn / GeekWire

Sana Biotechnology Opens $80M Manufacturing Facility in Bothell to Scale Cancer and Gene Therapy Production

Sana Biotechnology inaugurated its new 80,000 square-foot manufacturing facility in Bothell, Washington, dedicated to producing its proprietary cancer drug program and future therapies. The company, known for its gene-editing technology and multiple drugs in human trials including for cancer, autoimmune diseases, and type 1 diabetes, sees this expansion as a key step in advancing scalable cell and gene therapies.

Charlotte Schubert / GeekWire

Affini-T Therapeutics launched by Fred Hutch scientists including Juno co-founder Philip Greenberg to develop engineered TCR cancer therapies

Affini-T Therapeutics, founded by Fred Hutch scientists including Philip Greenberg (a Juno co-founder), Aude Chapuis and Thomas Schmitt, launched to develop T cell receptor (TCR) cancer immunotherapies that add engineered CD8 co-receptors and other gene edits. The Boston-headquartered company, led by CEO Jak Knowles, was unveiled at the J.P. Morgan Health Care Conference and will operate a research lab in Seattle.

John Cook / GeekWire

SPACs Let Founders Reach Public Markets Faster and Keep Larger Equity Stakes, Say Startup Observers

The article explains how SPACs (special purpose acquisition companies) let founders and early employees reach liquidity faster and often retain larger ownership stakes than through later-stage VC or private equity rounds. Using examples like Sana Biotechnology and Seattle entrepreneur Sujal Patel, it argues SPACs can preserve founders' equity by bypassing dilutive funding rounds.

John Cook / GeekWire

Sana Biotechnology Raises $587.5M in IPO, Debuts on Nasdaq as SANA with $6B Market Value

Sana Biotechnology raised $587.5 million by pricing 23.5 million shares at $25 in its IPO and began trading on Nasdaq under ticker SANA, with shares jumping about 40% on debut to close at $35.10. The 3-year-old Seattle gene-editing company, pre-revenue and led by former Juno executives, aims to use the proceeds to advance gene and cell therapies—including cancer treatments—and may file drug applications as early as 2022.

John Cook / GeekWire

Sana Biotechnology files IPO to raise up to $150M, aims to trade as SANA while advancing in‑body gene and cell therapies

Sana Biotechnology, founded less than three years ago with no revenue, filed to go public on Nasdaq under ticker SANA seeking to raise up to $150 million while developing gene and cell therapies aimed at controlling or modifying genes and treating cancers. The Seattle-area startup has raised over $700 million in venture funding, held $459 million in cash and equivalents at September-end, but carries a $316 million accumulated deficit.

Taylor Soper / GeekWire

Sana CEO Steve Harr Details Cell- and Gene-Therapy Plans After $700M+ Summer Raise

Sana Biotechnology CEO Steve Harr described the stealthy, Seattle-based gene and cell therapy startup’s plan to develop tools that repair and replace human cells to treat diseases and create new medicines, after raising more than $700 million this summer. Founded in 2019 by former Juno Therapeutics executives, the 250-person company emphasizes faster decision-making, focus, and communication as its competitive edge against larger rivals.

Organizations